You are here

Prices & Quotes - UK Markets - Novacyt S.A. (CDI) (NCYT)

Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Share Price:
Up 434.90p
Change Today:
102.90p
Market Cap:
307.15m
Sector:
Health Care Equipment & Services

Novacyt swings to first-half loss amid DHSC dispute

By Josh White

Date: Monday 27 Sep 2021

LONDON (ShareCast) - (Sharecast News) - Clinical diagnostics specialist Novacyt reported group consolidated unaudited revenue of 54m in its first half on Monday, down from 63.3m year-on-year, which excluded 40.8m of Department of Health and Social Care (DHSC) revenues, while that contract dispute continued.
The AIM-traded firm said non-DHSC revenue increased 20% for the six months ended 30 June, to 54m from 44.8m, supported by the growing UK private testing market.

It said it booked exceptional cost-of-sales of 35.8m in connection with the DHSC contract dispute, to write-down inventory and terminate supply agreements that it had built in anticipation of further DHSC demand, and to book the cost of products supplied to the DHSC in 2021 that had not been paid for.

The group's gross margin before exceptional items was 71%, delivering a gross profit of 38m.

After the exceptional DHSC-related cost of sales, Novacyt's gross margin dropped to 4%, delivering a gross profit of 2.3m.

Group adjusted EBITDA totalled 23.2m before exceptionals, down from 43.1m in the first half of 2020.

Novacyt reported an operating loss of 13.6m, swinging from a profit of 42.2m year-on-year, driven by the one-time exceptional cost of sales and stock write-down, while its loss after tax totalled 12.7m, compared to a profit of 35.1m a year earlier.

Cash at 30 June totalled 77.2m, with nil debt.

"During 2021, Novacyt has remained at the forefront in its response to the constantly changing global Covid-19 pandemic," said group chief executive officer Graham Mullis.

"We have launched 18 new Covid-19 products since the beginning of 2021 and we expect Novacyt to continue to play a major role in Covid-19 testing well into 2022.

"We also remain focused on strengthening our long-term position and executing against our strategy by building our product and instrument platforms and expanding our commercial infrastructure for growth beyond Covid-19."

At 0823 BST, shares in Novacyt were down 4.17% at 298.71p.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

NCYT Market Data

Currency UK Pounds
Price 434.90p
Change Today 102.90p
52 Week High 1,190.00p
52 Week Low 220.00p
Volume 3,301,081
Shares Issued 70.63m
Market Cap 307.15m

Performance Indicators

Compare performance with the sector and the market.

Key
Vs Market
Vs Sector
Value
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. half market star
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. half sector star
Price Trend
market
  1. full market star
  2. full market star
  3. full market star
  4. half market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. empty sector
Income
Not Available
Growth
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. half sector star
Price Chg 6m
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. half market star
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. full sector star
P/E
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. half market star
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. full sector star
PEG
market
  1. full market star
  2. full market star
  3. full market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. empty sector
  4. empty sector
  5. empty sector
Dividend Yield
Not Available
EPS Growth
Not Available
Operating Margin
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. half sector star

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

NCYT Dividends

No dividends found

Trades for 26-Nov-2021

Time Volume / Share Price
16:40 10 @ 430.00p
16:40 34 @ 430.00p
16:40 30 @ 430.00p
16:40 41 @ 430.00p
16:35 2,035 @ 434.90p

NCYT Key Personnel

CFO James McCarthy
CEO David Allmond